A comprehensive view of Capsules/Pills/Tablets. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Kyowa Kirin divests 13 mature brands to Grunenthal in deal worth US$83.0M, plus royalties; products include Abstral fentanyl sublingual tablets, PecFent fentanyl nasal spray, Moventig naloxegol, Adcal-D3 calcium and vitamin D3 for osteoporosis
Published: November 29, 2022 by Outsourcing-Pharma.com
Health Canada approves Bristol Myers Squibb’s Sotyktu deucravacitinib tablets to treat severe plaque psoriasis in adults; Psoriasis is a chronic inflammatory condition that affects nearly a million Canadians
Published: November 28, 2022 by Canada Newswire
AstraZeneca Pharma gets permission to import, market 10 mg Forxiga tablets in India
Published: November 28, 2022 by Accord Fintech (India)
GSK announces positive results in Phase 2 study showing its investigational tuberculosis medicine GSK3036656 is well-tolerated and shows early effectiveness at a low daily dose for 14 days
Published: November 14, 2022 by U.S. Regulated Equity Markets (Alternative Disclosure) via PUBT
GSK suspends manufacturing Panadol in Pakistan due to negative margins, government delay to address price issues; Panadol is the most commonly used OTC painkiller in Pakistan, with GSK making about 5.4 million Panadol tablets in the past year
Published: October 24, 2022 by Gulf News (United Arab Emirates)

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count